NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 178
(Total Views: 35)
Posted On: 01/24/2023 4:33:56 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival rate of only 10-12 months. The company’s Chief Executive Officer John Climaco recently participated in the Virtual Investor “Ask the CEO” Event and discussed that enrollment in the trial was approaching 70 patients against a target of 243, a remarkable achievement since it began about 14 months earlier. “Patients are a lifeblood of a trial like this,” Climaco said during the event, as quoted in a recent article. “Our target is recurring and refractory GBM patients, and sadly in this deadly cancer, almost everyone will recur. And when they do, they do not have any approved treatment option anywhere in the world… We’ve now offered those patients a chance at a chemotherapy that we believe can have efficacy and change the outcome of this disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival rate of only 10-12 months. The company’s Chief Executive Officer John Climaco recently participated in the Virtual Investor “Ask the CEO” Event and discussed that enrollment in the trial was approaching 70 patients against a target of 243, a remarkable achievement since it began about 14 months earlier. “Patients are a lifeblood of a trial like this,” Climaco said during the event, as quoted in a recent article. “Our target is recurring and refractory GBM patients, and sadly in this deadly cancer, almost everyone will recur. And when they do, they do not have any approved treatment option anywhere in the world… We’ve now offered those patients a chance at a chemotherapy that we believe can have efficacy and change the outcome of this disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)